(E)-2-(methylamino)octadec-4-ene-1,3-diol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (E)-2-(methylamino)octadec-4-ene-1,3-diol
• 化学式: C₁₉H₃₉NO₂
• 分子量: 313.5
• InChiKey: LUMQNHNDMLZNDJ-FOCLMDBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  22
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Sphingolipid derivatives and their methods of use
  申请人：——

  公开号：US20040039212A1

  公开（公告）日：2004-02-26

  Derivatives of sphingolipids of the formula: 1 are provided wherein the substituents are as defined in the specification and wherein there is at least one R 2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.

  本发明提供了公式1的鞘脂衍生物，其中取代基如规范中所定义，并且鞘脂衍生物中至少有一个R2取代基。这些化合物可用于治疗异常细胞增殖，包括良性和恶性肿瘤，促进细胞分化，诱导细胞凋亡，抑制蛋白激酶C，以及治疗炎症病症，牛皮癣，炎症性肠病以及在血管组织中形成斑块的平滑肌细胞增殖。本发明还包括一种触发线粒体细胞色素c释放的方法，包括向需要的宿主中投与有效量的鞘脂或其衍生物或前药。此外，本发明提供了一种治疗细菌感染的方法，包括那些影响结肠癌和其他肠道疾病的有效化合物的投与。
• Modulators of ceramidase and methods of used based thereon
  申请人：Bielawska Alicja

  公开号：US20050043534A1

  公开（公告）日：2005-02-24

  The present invention relates to compounds which can be used as inhibitors of mitochondrial ceramidase, in particular human mitochondrial ceramidase. The invention also relates to methods of designing and making the compounds, as well as methods screening for compounds that inhibit mitochondrial ceramidase. The invention also relates to the use of the compounds as a regulator of the level of ceramide by inhibiting ceramidase activity. The invention also relates to methods for the prevention and treatment of diseases associated with cell overproliferation and sphingolipid signal transduction including cancer, cardiovascular diseases, and inflammation.

  本发明涉及化合物，可以用作线粒体鞘氨醇酰水解酶的抑制剂，特别是人类线粒体鞘氨醇酰水解酶的抑制剂。本发明还涉及设计和制备这些化合物的方法，以及筛选抑制线粒体鞘氨醇酰水解酶的化合物的方法。本发明还涉及使用这些化合物作为通过抑制鞘氨醇酰水解酶活性调节鞘脂水平的调节剂。本发明还涉及预防和治疗与细胞过度增殖和鞘脂信号转导相关的疾病，包括癌症、心血管疾病和炎症的方法。
• Use of N-methyl-sphingosine as inhibitor of cell growth
  申请人：The Biomembrane Institute

  公开号：EP0381514A3

  公开（公告）日：1991-07-17

  A medicament for inhibiting growth of human and animal cells comprising: (1) a cell growth inhibitory amount of a one or more growth inhibitors comprising synthetically prepared sphingosine, synthetically prepared N-methyl-sphingosine or pharmaceutically acceptable salts thereof; and (2) a pharmaceutically acceptable carrier, diluent or excipient. A method for inhibiting growth of human and animal cells in vivo comprising contacting said cells with a cell growth inhibitory amount of one or more growth inhibitors comprising synthetically prepared sphingosine, synthetically prepared N-methyl-sphingosine or pharmaceutically acceptable salts thereof. A medicament for inhibiting growth of human and animal cells comprising: (1) A cell growth inhibitory amount of one or more growth inhibitors comprising sphingosine prepared from naturally occurring sphingolipid, N-methyl-sphingosine prepared from naturally occurring sphingolipid or pharmaceutically acceptable salts thereof; and (2) a pharmaceutically acceptable carrier, diluent or excipient. A method of inhibiting growth of human and animal cells in vivo comprising contacting said cells with a cell growth inhibitory amount of one or more growth inhibitors comprising sphingosine prepared from naturally occurring sphingolipid, N-methyl-sphingosine prepared from naturally occurring sphingolipid or pharmaceutically acceptable salts thereof.

  一种抑制人和动物细胞生长的药物，包括：(1)一种或多种生长抑制剂的细胞生长抑制量，包括合成制备的鞘氨醇，合成制备的N-甲基鞘氨醇或其药学上可接受的盐；和(2)药学上可接受的载体、稀释剂或赋形剂。一种抑制人和动物体内细胞生长的方法，包括使所述细胞与一种或多种生长抑制剂接触，这些生长抑制剂具有细胞生长抑制量，包括合成制备的鞘氨醇，合成制备的 N-甲基-鞘氨醇或其药学上可接受的盐。一种抑制人和动物细胞生长的药物，包括：(1) 一种或多种细胞生长抑制剂的细胞生长抑制量，这些生长抑制剂包括由天然鞘磷脂制备的鞘磷脂、由天然鞘磷脂制备的 N-甲基鞘磷脂或其药学上可接受的盐；以及 (2) 药学上可接受的载体、稀释剂或赋形剂。一种抑制体内人和动物细胞生长的方法，包括使所述细胞与一种或多种细胞生长抑制剂接触，这些生长抑制剂的细胞生长抑制量包括由天然鞘磷脂制备的鞘磷脂、由天然鞘磷脂制备的N-甲基鞘磷脂或其药学上可接受的盐。
• THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH $i(IN VITRO); METASTATIC POTENTIAL $i(IN VIVO) AND HUMAN PLATELET AGGREGATION
  申请人：ONCOMEMBRANE, INC.

  公开号：EP0565587B1

  公开（公告）日：1997-03-12
• EP0565587A4
  申请人：——

  公开号：EP0565587A4

  公开（公告）日：1994-06-01